Clinical trials recruiting for Malignant Neoplasm
13
Recruiting trials
49
US states with sites
19
Countries
8%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 5 |
| California | 3 |
| Virginia | 3 |
| Florida | 2 |
| North Dakota | 2 |
| South Dakota | 2 |
| Alabama | 1 |
| Alaska | 1 |
| Arizona | 1 |
| Arkansas | 1 |
| Colorado | 1 |
| Connecticut | 1 |
Top cities
Houston, Texas 4San Antonio, Texas 3Austin, Texas 2Fairfax, Virginia 2Fargo, North Dakota 2Los Angeles, California 2Orange, California 2Sacramento, California 2Sioux Falls, South Dakota 2Akron, Ohio 1
Self-screener
Recruiting trials
- A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
- A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant
- Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors
- Comparing the Diagnostic Sensitivity and Specificity of Pleural Fluid N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP) and Other Biochemical Gradient Criteria in Distinguishing Heart Failure and Non-heart Failure Related Pleural Effusions (CENTRE Study)
- Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
- DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
- DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
- Patient-Derived Xenografts to Reduce Cancer Health Disparities
- Project: Every Child for Younger Patients With Cancer
Related conditions
Trials recruiting for Malignant Neoplasm often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Melanoma 487Colorectal cancer 1359Pancreatic cancer 870Neoplasms by Site 11Neoplasms by Histologic Type 4Lymphoproliferative Disorders 5Solid Tumour 5Non-small cell lung cancer 507Malignancy 4
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Malignant Neoplasm trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.